Session

Late breaking abstracts: GI inflammation and infection - From IBD to eosinophilic oesophagitis

EFFICACY AND SAFETY OF FILGOTINIB AS MAINTENANCE THERAPY FOR PATIENTS WITH MODERATELY TO SEVERELY ACTIVE ULCERATIVE COLITIS: RESULTS FROM THE PHASE 2B/3 SELECTION STUDY
EFFICACY AND SAFETY OF FILGOTINIB AS MAINTENANCE THERAPY FOR PATIENTS WITH MODERATELY TO SEVERELY ACTIVE ULCERATIVE COLITIS: RESULTS FROM THE PHASE 2B/3 SELECTION STUDY

Late breaking abstracts: GI inflammation and infection - From IBD to eosinophilic oesophagitis  et al.

EFFICACY AND SAFETY OF FILGOTINIB AS INDUCTION THERAPY FOR PATIENTS WITH MODERATELY TO SEVERELY ACTIVE ULCERATIVE COLITIS: RESULTS FROM THE PHASE 2B/3 SELECTION STUDY
EFFICACY AND SAFETY OF FILGOTINIB AS INDUCTION THERAPY FOR PATIENTS WITH MODERATELY TO SEVERELY ACTIVE ULCERATIVE COLITIS: RESULTS FROM THE PHASE 2B/3 SELECTION STUDY

Late breaking abstracts: GI inflammation and infection - From IBD to eosinophilic oesophagitis  et al.

DUPILUMAB EFFICACY AND SAFETY IN ADULT AND ADOLESCENT PATIENTS WITH EOSINOPHILIC ESOPHAGITIS: RESULTS FROM PART A OF A RANDOMIZED, PLACEBO-CONTROLLED THREE-PART, PHASE 3 STUDY
DUPILUMAB EFFICACY AND SAFETY IN ADULT AND ADOLESCENT PATIENTS WITH EOSINOPHILIC ESOPHAGITIS: RESULTS FROM PART A OF A RANDOMIZED, PLACEBO-CONTROLLED THREE-PART, PHASE 3 STUDY

Late breaking abstracts: GI inflammation and infection - From IBD to eosinophilic oesophagitis  et al.

AN INVESTIGATIONAL ORAL MICROBIOME DRUG, CP101, FOR THE PREVENTION OF RECURRENT C. DIFFICILE INFECTION: A RANDOMIZED, PLACEBO-CONTROLLED, MULTI-CENTER TRIAL (PRISM3)
AN INVESTIGATIONAL ORAL MICROBIOME DRUG, CP101, FOR THE PREVENTION OF RECURRENT C. DIFFICILE INFECTION: A RANDOMIZED, PLACEBO-CONTROLLED, MULTI-CENTER TRIAL (PRISM3)

Late breaking abstracts: GI inflammation and infection - From IBD to eosinophilic oesophagitis  et al.

ETROLIZUMAB VERSUS PLACEBO IN TUMOR NECROSIS FACTOR ANTAGONIST NAIVE PATIENTS WITH ULCERATIVE COLITIS: RESULTS FROM THE RANDOMIZED PHASE 3 LAUREL TRIAL
ETROLIZUMAB VERSUS PLACEBO IN TUMOR NECROSIS FACTOR ANTAGONIST NAIVE PATIENTS WITH ULCERATIVE COLITIS: RESULTS FROM THE RANDOMIZED PHASE 3 LAUREL TRIAL

Late breaking abstracts: GI inflammation and infection - From IBD to eosinophilic oesophagitis  et al.

Item 1 - 5 / 5
1